Notice of Closed Meeting, 66267 [2018-27896]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 246 / Wednesday, December 26, 2018 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
Centers for Disease Control and
Prevention
[FR Doc. 2018–27895 Filed 12–21–18; 8:45 am]
[30Day–19–18ANU]
BILLING CODE 4163–18–P
Agency Forms Undergoing Paperwork
Reduction Act Review
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
amozie on DSK3GDR082PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)PS19–003, Using Real-time Prescription
and Insurance Claims Data to Support
the HIV Care Continuum.
Dates: March 6–7, 2019.
Time: 10:00 a.m.–5:00 p.m., (EDT).
Place: Teleconference, Centers for Disease
Control and Prevention, Room 1080, 8
Corporate Square Blvd., Atlanta, GA 30329.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Gregory
Anderson, M.S., M.P.H., Scientific Review
Officer, CDC, 1600 Clifton Road NE, Mailstop
E60, Atlanta, Georgia 30333, (404) 718–8833,
gca5@cdc.gov.
The Chief Operating Officer, Centers for
Disease Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2018–27896 Filed 12–21–18; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
20:07 Dec 21, 2018
Jkt 247001
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Communities
Organized To Prevent Arboviruses:
Assessment of Knowledge, Attitudes,
and Vector Control Practices and SeroPrevalence and Incidence of Arboviral
Infection in Ponce, Puerto Rico (COPA
Study) to the Office of Management and
Budget (OMB) for review and approval.
CDC previously published a ‘‘Proposed
Data Collection Submitted for Public
Comment and Recommendations’’
notice on July 20, 2018 to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
66267
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, 725 17th Street NW,
Washington, DC 20503 or by fax to (202)
395–5806. Provide written comments
within 30 days of notice publication.
Proposed Project
Communities Organized To Prevent
Arboviruses: Assessment of Knowledge,
Attitudes, and Vector Control Practices
and Sero-Prevalence and Incidence of
Arboviral Infection in Ponce, Puerto
Rico (COPA)—Existing Collection in use
without an OMB Control Number—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Recent years have seen the emergence
of two epidemic arthropod-borne
viruses (arboviruses) that are
transmitted by Aedes aegypti
mosquitoes. Chikungunya virus was
introduced into the Caribbean in late
2013, and caused large epidemics of
fever with severe joint pain throughout
the Caribbean and Americas in 2014.
Zika virus was first detected in the
Americas in Brazil in 2014, spread
throughout the Americas, and has since
been associated with devastating birth
defects, Guillain-Barre syndrome, and is
the first arbovirus that can also be
transmitted through sexual contact. In
addition, the four viruses that cause
dengue were introduced to the Americas
over the past several hundred years and
have since become endemic, and yellow
fever virus has recently caused large
outbreaks in Brazil and there is risk of
importation to other counties in the
Americas.
In all of these cases, the public health
response to the spread of these
arboviruses throughout the tropics,
where their mosquito vectors thrive, has
been hampered by a lack of sustainable
and effective interventions to prevent
infection with any of these arboviruses
at the community level. Additionally,
the rapid speed with which new
arboviruses spread does not often
provide the time needed to plan and
implement community-level
interventions to decrease disease
transmission. Although several
candidate vaccines for chikungunya and
Zika are currently in clinical
development, none are yet available. A
dengue vaccine has been licensed in
several countries, but initial analyses
have suggested that decades will be
needed before it results in reduction in
transmission of dengue virus.
In recent years, community based
strategies for vector control have been
E:\FR\FM\26DEN1.SGM
26DEN1
]]>Agencies
[Federal Register Volume 83, Number 246 (Wednesday, December 26, 2018)]
[Notices]
[Page 66267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-27896]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Chief Operating
Officer, CDC, pursuant to Public Law 92-463. The grant applications and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)-PS19-003, Using Real-time
Prescription and Insurance Claims Data to Support the HIV Care
Continuum.
Dates: March 6-7, 2019.
Time: 10:00 a.m.-5:00 p.m., (EDT).
Place: Teleconference, Centers for Disease Control and
Prevention, Room 1080, 8 Corporate Square Blvd., Atlanta, GA 30329.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop E60,
Atlanta, Georgia 30333, (404) 718-8833, gca5@cdc.gov.
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal
Register notices pertaining to announcements of meetings and other
committee management activities, for both the Centers for Disease
Control and Prevention and the Agency for Toxic Substances and
Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2018-27896 Filed 12-21-18; 8:45 am]
BILLING CODE 4163-18-P
